A t least five million people in the United States have been infected with the hepatitis C virus (HCV) 1 . That's about five times as many people as are infected with HIV. A sound publichealth response to the HCV epidemic requires urgent investment in prevention, testing, treatment and research -investments that were made for HIV -to avert greater financial costs and loss of life. Indeed, a January 2010 report by the Institute of Medicine (IOM), part of the US National Academy of Sciences, warned that viral hepatitis will remain out of control unless adequate resources are devoted to prevention, control and surveillance 2 . This is not the response that we are witnessing. The US government has all but ignored the threat of HCV and is underfunding prevention, treatment and research into the disease (see 'US Response to the HIV and viral hepatitis epidemics'). The Action Plan to Prevent, Care and Treat Viral Hepatitis, which was released in May 2011 by the US Department of Health and Human Services in response to the IOM report, does not include an intention to increase funding for viral hepatitis.
Control of any epidemic starts with an accurate understanding of the magnitude of the problem, but the scope of the HCV epidemic in the United States is poorly understood. For example, the Centers for Disease Control and Prevention (CDC) estimate of the prevalence of HCV infection in the United States is four million people 3 . But this relies on data from a national household survey that has long been known to suffer from non-response bias and to exclude high-risk populations such as homeless people and prisoners. This survey underestimated 4 . The CDC's surveillance system covers people who are not homeless or institutionalized, have nothing to fear from the authorities, have access to health care, feel ill when they contract HCV infection and visit a doctor when they feel ill. But HCV disproportionately affects groups for whom those attributes often don't hold true (see 'Hepatitis C is a disease of the marginalized').
Even if the extent of the epidemic is unclear, basic prevention strategies could still be implemented. Prevention is the cornerstone of disease control, so the lack of funding in this area is especially troubling. Some have argued that HCV infection cannot be prevented. But there is strong evidence that the interventions that decreased HIV transmission among drug users -communitybased outreach and education, testing and counselling, access to sterile syringes and substance-use treatment -also markedly reduced HCV transmission 7 . Once drug users learned about how HIV was spread, and barriers to obtaining sterile injection equipment were lowered, users eagerly adopted safer injection techniques, and both HIV and HCV incidence rates fell by as much as an order of magnitude from the late 1980s to the late 1990s. HCV transmission rates were, however, far higher than those for HIV to begin with, and they remain unacceptably high. But HCV incidence rates in injection drug users fell from 15-20% per month in the 1980s to 10-25% per year after HIV prevention interventions were introduced. The median time between the first use of injection drugs and HCV infection rose from 3-4 months in the 1980s to 4-7 years in the
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1990s, opening a window of opportunity in which to slow the spread of the virus. But effective preventive interventions are not available in many locations and are poorly funded where they do exist. And research on new interventions to reduce transmission further, which is urgently needed, is not a priority at the National Institutes of Health (NIH).
About half of all HCV infections can be cured with a single 6-12-month course of therapy, and new drug regimens will be more effective. But the resources to provide testing and deliver care are missing. US government policy recommends that all adults be screened for HIV, and there has been significant progress towards that goal: 83 million people have been tested, and CDC grants provide funding for another 1.4 million tests each year. But no such policy or funding supports HCV testing -even though more than ten times as many Americans have undiagnosed HCV as have undiagnosed HIV infection, and half or more of them could be cured with a single 6-12 month course of therapy. Moreover, public-health programmes stop at the doors of most correctional facilities, abandoning the infected and those at risk at the moment when providing prevention and treatment services would be most practical. In 2009, the IOM put the development of better treatment strategies for at-risk populations such as injection drug users on its list of the nation's top research priorities 8 -but the NIH has yet to respond to the call. As a result, liver disease rates will continue to rise, and about 150,000 Americans will die from viral hepatitis in the next decade 2 . Public and private healthcare expenditure on hepatitis C, which is estimated at US$30 billion today, is expected to exceed US$80 billion, with an increasing proportion of the cost falling to public sources 9 . If we fail to act now, these expenses will overwhelm our already overburdened public healthcare system.
The United States launched a vibrant response to the HIV/AIDS epidemic and made great advances in surveillance, prevention, care and treatment by investing in research and services in these areas. A timely, proportionate response to HCV will require leadership and resources. Nothing less will mitigate the extraordinary toll that viral hepatitis could take on the public's health and on the healthcare system. ■ Brian R. Edlin 
